Successful treatment of chronic stromal acanthamoeba keratitis with oral voriconazole monotherapy

Cornea

Volumn 29, Issue 9, 2010, Pages 1066-1068

  Tu, Elmer Y ^a   Joslin, Charlotte E ^a,b   Shoff, Megan E ^c  

^a Department of Ophthalmology and Visual Science ^*  (Hong Kong)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

Author keywords

Acanthamoeba; keratitis; stromal interstitial keratitis; voriconazole

Indexed keywords

CHLORHEXIDINE GLUCONATE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN A; GATIFLOXACIN; POLY(HEXAMETHYLENEBIGUANIDE); PROPAMIDINE ISETHIONATE; VORICONAZOLE; ANTIPROTOZOAL AGENT; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ACANTHAMOEBA; ADOLESCENT; ARTICLE; BLURRED VISION; CASE REPORT; CONTACT LENS; DRUG WITHDRAWAL; FEMALE; HUMAN; KERATITIS; LIVER FUNCTION TEST; MALE; MONOTHERAPY; PRIORITY JOURNAL; TREATMENT RESPONSE; VISUAL ACUITY; ACANTHAMOEBA KERATITIS; CHRONIC DISEASE; CORNEA STROMA; ORAL DRUG ADMINISTRATION; PARASITOLOGY;

ACANTHAMOEBA KERATITIS; ADMINISTRATION, ORAL; ADOLESCENT; ANTIPROTOZOAL AGENTS; CHRONIC DISEASE; CORNEAL STROMA; FEMALE; HUMANS; MALE; PYRIMIDINES; TRIAZOLES; VORICONAZOLE;

EID: 77956230063     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181cbfa2c     Document Type: Article

References (15)

1. Kitzmann AS, Goins KM, Sutphin JE, et al. Keratoplasty for treatment of Acanthamoeba keratitis. Ophthalmology. 2009;116:864-869.
2. Schuster FL, Guglielmo BJ, Visvesvara GS. In-vitro activity of miltefosine and voriconazole on clinical isolates of free-living amebas: Balamuthia mandrillaris, Acanthamoeba spp., and Naegleria fowleri. J Eukaryot Microbiol. 2006;53:121-126.
3. Hirst LW, Green WR, Merz W, et al. Management of Acanthamoeba keratitis. A case report and review of the literature. Ophthalmology. 1984; 91:1105-1111.
4. Moore MB, McCulley JP, Luckenbach M, et al. Acanthamoeba keratitis associated with soft contact lenses. Am J Ophthalmol. 1985;100:396-403.
5. Driebe WT Jr, Stern GA, Epstein RJ, et al. Acanthamoeba keratitis. Potential role for topical clotrimazole in combination chemotherapy. Arch Ophthalmol. 1988;106:1196-1201.
6. Ishibashi Y, Matsumoto Y, Kabata T, et al. Oral itraconazole and topical miconazole with debridement for Acanthamoeba keratitis. Am J Ophthalmol. 1990;109:121-126.
7. Walia R, Montoya JG, Visvesvera GS, et al. A case of successful treatment of cutaneous Acanthamoeba infection in a lung transplant recipient. Transpl Infect Dis. 2007;9:51-54.
8. Kaul DR, Lowe L, Visvesvara GS, et al. Acanthamoeba infection in a patient with chronic graft-versus-host disease occurring during treatment with voriconazole. Transpl Infect Dis. 2008;10:437-441.
9. Vemulakonda GA, Hariprasad SM, Mieler WF, et al. Aqueous and vitreous concentrations following topical administration of 1% vorico-nazole in humans. Arch Ophthalmol. 2008;126:18-22.
10. Ben Salah S, Makni F, Cheikrouhou F, et al. [Acanthamoeba keratitis: about the first two Tunisian cases]. Bull Soc Pathol Exot. 2007;100:41-42.
11. Yang YF, Matheson M, Dart JK, et al. Persistence of Acanthamoeba antigen following Acanthamoeba keratitis. Br J Ophthalmol. 2001;85: 277-280.
12. Gooi P, Lee-Wing M, Brownstein S, et al. Acanthamoeba keratitis: persistent organisms without inflammation after 1 year of topical chlorhexidine. Cornea. 2008;27:246-248.
13. Mathers W. Use of higher medication concentrations in the treatment of Acanthamoeba keratitis. Arch Ophthalmol. 2006;124:923.
14. Tu EY, Joslin CE, Sugar J, et al. Prognostic factors affecting visual outcome in Acanthamoeba keratitis. Ophthalmology. 2008;115: 1998-2003.
15. Lim N, Goh D, Bunce C, et al. Comparison of polyhexamethylene biguanide and chlorhexidine as monotherapy agents in the treatment of Acanthamoeba keratitis. Am J Ophthalmol. 2008;145:130-135.